Home Cart Sign in  
Chemical Structure| 501364-82-5 Chemical Structure| 501364-82-5

Structure of INO-1001
CAS No.: 501364-82-5

Chemical Structure| 501364-82-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

INO-1001 is an isoindolinone derivative and potent inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with chemosensitization and radiosensitization properties. INO-1001 inhibits PARP, which may result in inhibition of tumor cell DNA repair mechanisms and, so, tumor cell resistance to chemotherapy and radiation therapy. PARP enzymes are activated by DNA breaks and have been implicated in the repair of DNA single-strand breaks (SSB). NOTE: as of 7/29/2016, many vendors are selling INO-1001 with wrong structure (3-aminobenzamide, CAS# 3544-24-9)

Synonyms: INO-1001

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of INO-1001

CAS No. :501364-82-5
Formula : C23H25N3O4S
M.W : 439.53
SMILES Code : O=S(C1=CC(C2)=C(C3=C2C4=C(C(N3)=O)C=CC=C4)C=C1)(NCCCN5CCOCC5)=O
Synonyms :
INO-1001
MDL No. :MFCD19443171
InChI Key :LTZVLHHIAUKGBP-UHFFFAOYSA-N
Pubchem ID :9889396

Safety of INO-1001

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of INO-1001

epigenetics
DNA

Isoform Comparison

Biological Activity

Description
INO-1001, a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor, heightens radiation sensitivity and augments radiation-induced cell death by disrupting DNA repair mechanisms, leading to necrotic cell demise[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00271167 Heart Diseases|Postoperative C... More >>omplications Less << PHASE2 TERMINATED 2025-06-06 Beth Israel Deaconess Medical ... More >>Center, Boston, Massachusetts, 02215, United States|University of Oklahoma, Oklahoma, Oklahoma, 73152, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Methodist Hospital, Houston, Texas, 77030, United States|Sydney, New South Wales, Australia|Ashford Cardiac Clinic / Adelaide Cardiac, Adelaide, South Australia, Australia|St. Vincent's Hospital, Melbourne, Victoria, 3065, Australia|Royal Perth Hospital, Perth, Western Australia, 6000, Australia|Care Hospital, Hyderabad, India|Escorts Heart Institute and Research Centre, New Delhi, 110029, India|Wolfson Medical Centre, Holon, 58100, Israel|Jerusalem, Israel Less <<
NCT00271765 Acute Myocardial Infarction PHASE2 COMPLETED 2025-06-06 Holy Cross Hospital, Fort Laud... More >>erdale, Florida, 33308, United States|Porter Hospital, Valparaiso, Indiana, 46383, United States|St. Paul Heart Clinic, St. Paul, Minnesota, 55102, United States|Newark, New Jersey, United States|Toledo Hospital, Toledo, Ohio, 43606, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Black Hills Cardiovascular Research, Rapid City, South Dakota, 57701, United States|Burlington, Vermont, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|West Virginia University, Morgantown, West Virginia, 26506, United States|Rambam Medical Center, Haifa, 31096, Israel|Meir Medical Center, Kfar Saba, 95847, Israel|Hasharon Medical Center, Petach Tikva, 49100, Israel|Rabin Medical Center, Petach Tikva, 49100, Israel|Rehovot, Israel|Assaf Harofe Medical Centre, Zerifin, Israel Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.38mL

2.28mL

1.14mL

22.75mL

4.55mL

2.28mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories